anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
== Adverse effects == Data for safety and efficacy of copanlisib are described in the consumer-targeted FDA Drug Trial Snapshot. Copanlisib can cause serious side effects including infections, hyperglycemia, hypertension, pneumonitis, neutropenia and skin rashes. The most common side effects of copanlisib are hyperglycemia, diarrhea, decreased general strength and energy, hypertension, leukopenia, neutropenia, nausea, lower respiratory tract infections and thrombocytopenia.
Library of Ruina is an indie deck-building role-playing game developed and published by Project Moon. Initially released for Windows and Xbox One on August 10, 2021, it is a sequel to the 2018 game Lobotomy Corporation. The game generally received positive reviews for PC, but mixed to negative reviews on console. A sequel, Limbus Company, was released in 2023 for Windows, iOS, and Android devices. The light novel The Distortion Detective is a side story that takes place during the events of Library of Ruina. Another light novel, Leviathan, was illustrated as a manga, taking place between Library of Ruina's true ending and the start of Limbus Company.
In the wild, adult Komodo dragons usually weigh around 70 kg (150 lb), although captive specimens often weigh more. According to Guinness World Records, an average adult male will weigh 79 to 91 kg (174 to 201 lb) and measure 2.59 m (8.5 ft), while an average female will weigh 68 to 73 kg (150 to 161 lb) and measure 2.29 m (7.5 ft). The largest verified specimen in captivity was 3.1–3.13 m (10 ft 2 in – 10 ft 3 in) long and weighed 166 kg (366 lb), including its undigested food. The largest wild specimen had a length 3.04 m (10 ft), a snout-vent length (SVL) 1.54 m (5 ft 1 in) and a mass of 81.5 kg (180 lb) excluding stomach contents. The heaviest reached a mass of 87.4 kg (193 lb). The study noted that weights greater than 100 kg (220 lb) were possible but only after the animal had consumed a large meal. The Komodo dragon has a tail as long as its body, as well as about 60 frequently replaced, serrated teeth that can measure up to 2.5 cm (1 in) in length. Its saliva is frequently blood-tinged because its teeth are almost completely covered by gingival tissue that is naturally lacerated during feeding. It also has a long, yellow, deeply forked tongue.
Sources: en.wikipedia.org
UK Telegraph Newspaper (September 2008) - One woman dead, another critically ill after eating Death Cap fungi AmericanMushrooms.com - The Death Cap Mushroom Amanita phalloides Amanita phalloides: the death cap Amanita phalloides: Invasion of the Death Cap Key to species of Amanita Section Phalloideae from North and Central America - Amanita studies website California Fungi—Amanita phalloides Death cap in Australia - ANBG website On the Trail of the Death Cap Mushroom from National Public Radio "Amanita phalloides". The Encyclopedia of Life.
== Discovery == The ANGPTL8 gene was discovered in 2012 as Lipasin, RIFL, and ANGPTL8. In 2013 it was suggested by Melton and Yi from Harvard that ANGPTL8 promotes mouse pancreatic islet cell proliferation. These results led the authors to propose an alternative name for ANGPTL8, betatrophin. However, the link between ANGPTL8 and islet proliferation was quickly proven false by other researchers. In fact, in December 2016 the original paper by Melton and Yi was retracted, putting the link between ANGPTL8 and islets cells to rest. Nevertheless, the name betatrophin continues to be used. Given the homology of ANGPTL8 with ANGPTL4 and ANGPTL3, and considering that ANGPTL8 does not promote beta cell proliferation, the name betatrophin should be abandoned in favor of ANGPTL8.
5-HTP is decarboxylated to serotonin (5-hydroxytryptamine or 5-HT) by the enzyme aromatic-L-amino-acid decarboxylase with the help of vitamin B6. This reaction occurs both in nervous tissue and in the liver. 5-HTP crosses the blood–brain barrier, while 5-HT does not. Excess 5-HTP, especially when administered with vitamin B6, is thought to be metabolized and excreted. Though 5-HTP is found in food only in insignificant quantities, it is a chemical involved intermediately in the metabolism of tryptophan, an amino acid found in all unfractionated foods, with lower total amino acid content correlating with increased tryptophan absorption.
Sources: en.wikipedia.org
In 1957, the Ghana Armed Forces (GAF) consisted of its headquarters, support services, three battalions of infantry and a reconnaissance squadron with armoured vehicles. President Nkrumah aimed at rapidly expanding the GAF to support the United States of Africa ambitions. Thus, in 1961, 4th and 5th Battalions were established, and in 1964 6th Battalion was established, from a parachute airborne unit originally raised in 1963. Today, Ghana is a regional power and regional hegemon. In his book Shake Hands with the Devil, Canadian Forces commander Roméo Dallaire highly rated the GAF soldiers and military personnel. The military operations and military doctrine of the GAF are conceptualised in the constitution, Ghana's Law on Armed Force Military Strategy, and Kofi Annan International Peacekeeping Training Centre agreements to which GAF is attestator. GAF military operations are executed under the auspices and imperium of the Ministry of Defence. Ghana has experienced political violence in the past and 2017 has thus far seen an upward trend in incidents motivated by political grievances.
She was active in that role for over ten years. During that time she was also elected into the Association of American Physicians. In 2015 Dr. Huttenlocher was inducted as a Member of the National Academy of Medicine "for her pioneering studies of cell migration and alterations of cell migration in human diseases." In 2017, Huttenlocher was awarded a UW2020 grant to support her project "Engineering leukocytes generated from human iPS cells to treat human disease." At the same time, she was also elected a Fellow of the American Society for Cell Biology. In May 2020, Huttenlocher was named the Anna Ruth Brummett Professor of Pediatrics and Medical Microbiology and Immunology Chair in honor of her "major contributions to the advancement of knowledge." The following year, she was part of a large team of researchers from the University of Wisconsin Carbone Cancer Center recognized with the Society for the Immunotherapy of Cancer’s Team Science Award for "long-standing contribution to the field of cancer immunotherapy over the past 35 years." Huttenlocher's recent research projects include "Cell migration and wound repair" and "Imaging immunometabolism in live animals during host defense." In 2023, Huttenlocher published the book "From Loss to Memory: Behind the Discovery of Synaptic Pruning". It describes the discovery of synaptic pruning and its current relevance to early learning, autism, schizophrenia and Alzheimer's disease.
The three substrates of this enzyme are L-tryptophan, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are indole-3-pyruvic acid, ammonia, reduced NADH, and a proton. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH2 group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-tryptophan:NAD(P)+ oxidoreductase (deaminating). Other names in common use include NAD(P)+-L-tryptophan dehydrogenase, L-tryptophan dehydrogenase, L-Trp-dehydrogenase, and TDH. This enzyme has at least one effector, calcium.
To describe the types of protein–protein interactions (PPIs), proteins can interact in a "transient" way (to produce some specific effect in a short time, like signal transduction) or to interact with other proteins in a "stable" way to form complexes that become molecular machines within the living systems. A protein complex assembly can result in the formation of homo-oligomeric or hetero-oligomeric complexes. In addition to the conventional complexes, as enzyme-inhibitor and antibody-antigen, interactions can also be established between domain-domain and domain-peptide. Another important distinction to identify protein–protein interactions is the way they have been determined, since there are techniques that measure direct physical interactions between protein pairs, named "binary" methods, while there are other techniques that measure physical interactions among groups of proteins, without pairwise determination of protein partners, named "co-complex" methods.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.